Fengxi Su

7.9k total citations · 5 hit papers
85 papers, 5.7k citations indexed

About

Fengxi Su is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Fengxi Su has authored 85 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Cancer Research, 40 papers in Oncology and 27 papers in Pathology and Forensic Medicine. Recurrent topics in Fengxi Su's work include Breast Cancer Treatment Studies (35 papers), Breast Lesions and Carcinomas (26 papers) and HER2/EGFR in Cancer Research (10 papers). Fengxi Su is often cited by papers focused on Breast Cancer Treatment Studies (35 papers), Breast Lesions and Carcinomas (26 papers) and HER2/EGFR in Cancer Research (10 papers). Fengxi Su collaborates with scholars based in China, United States and Hong Kong. Fengxi Su's co-authors include Erwei Song, Herui Yao, Chang Gong, Qiang Liu, Fengyan Yu, Judy Lieberman, Xiaoqu Hu, Yijun Huang, Qiuhui Pan and Pengcheng Zhu and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Fengxi Su

82 papers receiving 5.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells

2007 1.5k citations Fengyan Yu, Herui Yao et al. profile →
A Cytoplasmic NF-κB Interacting Long Noncoding RNA Blocks IκB Phosphorylation and Suppresses Breast Cancer Metastasis

2015 746 citations Bodu Liu, Lijuan Sun et al. Cancer Cell profile →
Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells

2019 581 citations Jianing Chen, Dong Yin et al. profile →
Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells

2011 581 citations Fengxi Su, Yujie Liu et al. profile →
NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death

2018 345 citations Di Huang, Fengxi Su et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fengxi Su China	26	3.7k	3.6k	1.5k	576	463	85	5.7k
Chung‐Ji Liu Taiwan	45	4.5k 1.2×	3.5k 1.0×	1.9k 1.3×	515 0.9×	555 1.2×	159	6.9k
Longbang Chen China	49	5.9k 1.6×	4.7k 1.3×	1.7k 1.1×	587 1.0×	771 1.7×	155	8.1k
Kensuke Kumamoto Japan	32	4.5k 1.2×	3.3k 0.9×	1.3k 0.9×	489 0.8×	701 1.5×	182	6.3k
Kenjiro Sawada Japan	40	2.7k 0.7×	1.5k 0.4×	1.3k 0.9×	1.0k 1.7×	409 0.9×	137	5.0k
Cristina Peña Spain	37	3.5k 1.0×	2.1k 0.6×	1.9k 1.3×	516 0.9×	479 1.0×	73	5.4k
Baocun Sun China	39	2.8k 0.8×	1.5k 0.4×	1.7k 1.1×	478 0.8×	783 1.7×	145	4.6k
Mariano Monzó Spain	41	4.0k 1.1×	3.1k 0.8×	1.7k 1.1×	339 0.6×	813 1.8×	143	6.1k
Francesca Lovat United States	33	3.5k 1.0×	3.1k 0.9×	708 0.5×	521 0.9×	345 0.7×	52	4.7k
Limin Xia China	39	2.8k 0.8×	1.4k 0.4×	1.0k 0.7×	594 1.0×	512 1.1×	142	4.1k

Countries citing papers authored by Fengxi Su

Since Specialization

Citations

This map shows the geographic impact of Fengxi Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengxi Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengxi Su more than expected).

Fields of papers citing papers by Fengxi Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengxi Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengxi Su. The network helps show where Fengxi Su may publish in the future.

Co-authorship network of co-authors of Fengxi Su

This figure shows the co-authorship network connecting the top 25 collaborators of Fengxi Su. A scholar is included among the top collaborators of Fengxi Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengxi Su. Fengxi Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hua, Shao‐Ying, Biao Yang, Xinchang Zhang, et al.. (2025). GDPGO-SAM: An Unsupervised Fine Segmentation of Desert Vegetation Driven by Grounding DINO Prompt Generation and Optimization Segment Anything Model. Remote Sensing. 17(4). 691–691. 1 indexed citations

Yu, Fengyan, Juan Feng, Wei Tang, et al.. (2024). Expression of Concern: Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5. Clinical Cancer Research. 30(13). 2847–2847. 1 indexed citations

Wu, Wei, Jiewen Chen, Heran Deng, et al.. (2021). Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. BMC Cancer. 21(1). 862–862. 11 indexed citations

Hu, Tingting, Shunrong Li, Heng Huang, et al.. (2020). Multicentre, randomised, open-label, non-inferiority trial comparing the effectiveness and safety of ductal lavage versus oral corticosteroids for idiopathic granulomatous mastitis: a study protocol. BMJ Open. 10(10). e036643–e036643. 4 indexed citations

Wang, Yan, Kai Chen, Yaping Yang, et al.. (2019). Incidence and survival outcomes of early male breast cancer: a population-based comparison with early female breast cancer. Annals of Translational Medicine. 7(20). 536–536. 14 indexed citations

Chen, Kai, Liling Zhu, Lili Chen, et al.. (2019). Circumferential Shaving of the Cavity in Breast-Conserving Surgery: A Randomized Controlled Trial. Annals of Surgical Oncology. 26(13). 4256–4263. 13 indexed citations

Pan, Zihao, Liling Zhu, Jianguo Lai, et al.. (2018). Predicting initial margin status in breast cancer patients during breast-conserving surgery. OncoTargets and Therapy. Volume 11. 2627–2635. 7 indexed citations

Zhu, Yinghua, Yujie Liu, Chao Zhang, et al.. (2018). Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. Nature Communications. 9(1). 1595–1595. 110 indexed citations

Li, Mingzhu, Kai Chen, Fengtao Liu, et al.. (2017). Nipple sparing mastectomy in breast cancer patients and long-term survival outcomes: An analysis of the SEER database. PLoS ONE. 12(8). e0183448–e0183448. 25 indexed citations

10.

Chen, Kai, Shunrong Li, Qian Li, et al.. (2016). Breast-conserving Surgery Rates in Breast Cancer Patients With Different Molecular Subtypes. Medicine. 95(8). e2593–e2593. 19 indexed citations

11.

Liu, Bodu, Lijuan Sun, Qiang Liu, et al.. (2015). A Cytoplasmic NF-κB Interacting Long Noncoding RNA Blocks IκB Phosphorylation and Suppresses Breast Cancer Metastasis. Cancer Cell. 27(3). 370–381. 746 indexed citations breakdown →

12.

Yang, Yaping, Jieqiong Liu, Ran Gu, et al.. (2015). Influence of factors on mammographic density in premenopausal Chinese women. European Journal of Cancer Prevention. 25(4). 306–311. 21 indexed citations

13.

Gong, Chang, Yan Nie, Shaohua Qu, et al.. (2014). miR-21 Induces Myofibroblast Differentiation and Promotes the Malignant Progression of Breast Phyllodes Tumors. Cancer Research. 74(16). 4341–4352. 75 indexed citations

14.

Jia, Weijuan, et al.. (2014). HER2-enriched Tumors Have the Highest Risk of Local Recurrence in Chinese Patients Treated with Breast Conservation Therapy. Asian Pacific Journal of Cancer Prevention. 15(1). 315–320. 16 indexed citations

15.

Jia, Haixia, Weijuan Jia, Yaping Yang, et al.. (2014). HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy. World Journal of Surgical Oncology. 12(1). 289–289. 20 indexed citations

16.

Huang, Di, Shicheng Su, Xiuying Cui, et al.. (2014). Nerve Fibers in Breast Cancer Tissues Indicate Aggressive Tumor Progression. Medicine. 93(27). e172–e172. 63 indexed citations

17.

Li, Shunrong, Jieqiong Liu, Yaping Yang, et al.. (2014). Impact of atypical hyperplasia at margins of breast-conserving surgery on the recurrence of breast cancer. Journal of Cancer Research and Clinical Oncology. 140(4). 599–605. 10 indexed citations

18.

Wu, Jiannan, Shunrong Li, Weijuan Jia, & Fengxi Su. (2011). Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology. 137(10). 1505–1510. 30 indexed citations

19.

Su, Yi, Lijuan Chen, Jianrong He, et al.. (2011). Urinary rubidium in breast cancers. Clinica Chimica Acta. 412(23-24). 2305–2309. 27 indexed citations

20.

Hu, Xiaoqu, Fengxi Su, Li Qin, et al.. (2006). Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. Biochemical and Biophysical Research Communications. 346(3). 778–785. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact